Detailed price information for Soleno Therapeutics Inc (SLNO-Q) from The Globe and Mail including charting and trades.

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ("Edgewise" or "the Company") ...

Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX). Such investors are ...

Detailed price information for Mereo Biopharma Group Plc ADR (MREO-Q) from The Globe and Mail including charting and trades.

Edgewise Therapeutics Inc. (NASDAQ:EWTX) is one of the best up and coming stocks to invest in now. On June 26, Edgewise Therapeutics announced positive results from its sevasemten program for ...

Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) has earned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat.com ...

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights Provided by PR Newswire May 8, 2025, 12:00:00 PM ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the fourth quarter and full year of 2024 and recent business ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is a biopharmaceutical company, focuses on developing therapies for the treatment of muscle disorders.

BOULDER, Colo. - Edgewise Therapeutics Inc. (NASDAQ:EWTX), a biopharmaceutical company focused on muscle disease treatment with a market capitalization of $2.6 billion, today announced significant ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest ...